GOVX insider filings
GeoVax Labs, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen GOVX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Brown Steven Collier — Director | 1 | — | — | — |
| Uppal Manpreet — Director | 1 | — | — | — |
Recent insider filings — GeoVax Labs, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 3 | Brown Steven Collier — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-03 | 3 | Uppal Manpreet — Director | Holdings only — no transactions reported | EDGAR |
| 2026-06-22 | 4 | Morgan Jayne — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Lemerond Nicole — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Sharkey John W. — VP, Business Development | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Kollintzas Dean G — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Reynolds Mark — CFO | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | SPENCER JOHN N JR — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | NEWMAN MARK J — Chief Scientific Officer | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | DODD DAVID A — President, CEO, Director | Grant/award (A): 29,300 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | CHASE RANDAL D — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | SPENCER JOHN N JR — Director | Purchase (P): 10,000 @ $0.55 | EDGAR |
| 2025-08-08 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Purchase (P): 1,107 @ $0.67 | EDGAR |
| 2025-06-06 | 4 | Morgan Jayne — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Lemerond Nicole — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Sharkey John W. — VP, Business Development | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kollintzas Dean G — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Reynolds Mark — CFO | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | SPENCER JOHN N JR — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | NEWMAN MARK J — Chief Scientific Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | DODD DAVID A — President, CEO, Director | Grant/award (A): 185,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CHASE RANDAL D — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | SPENCER JOHN N JR — Director | Purchase (P): 10,000 @ $0.98 | EDGAR |
| 2025-04-10 | 4 | Sharkey John W. — VP, Business Development | Purchase (P): 6,000 @ $0.99 | EDGAR |
| 2025-04-01 | 4 | DODD DAVID A — President, CEO, Director | Purchase (P): 10,000 @ $1.08 | EDGAR |
| 2025-03-31 | 4 | Reynolds Mark — CFO | Purchase (P): 6,800 @ $1.08 | EDGAR |
| 2024-08-14 | 4 | Morgan Jayne — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Lemerond Nicole — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Sharkey John W. — VP, Business Development | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Kollintzas Dean G — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Reynolds Mark — CFO | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | SPENCER JOHN N JR — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | NEWMAN MARK J — Chief Scientific Officer | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | DODD DAVID A — President, CEO, Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | CHASE RANDAL D — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 8,050 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | DODD DAVID A — President, CEO, Director | Purchase (P): 8,000 @ $1.95 | EDGAR |
| 2024-02-22 | 4 | DODD DAVID A — President, CEO, Director | Purchase (P): 520 @ $2.15 · Purchase (P): 8,209 @ $2.27 | EDGAR |
| 2024-02-07 | 4 | Reynolds Mark — CFO | Purchase (P): 2,000 @ $2.77 | EDGAR |
| 2023-12-26 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Purchase (P): 6,944 @ $0.36 | EDGAR |
| 2023-09-27 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Purchase (P): 9,653 @ $0.52 | EDGAR |
| 2023-08-28 | 4 | DODD DAVID A — President, CEO, Director | Purchase (P): 35,087 @ $0.57 | EDGAR |
| 2023-08-21 | 4 | Reynolds Mark — CFO | Purchase (P): 10,000 @ $0.52 | EDGAR |
| 2023-08-14 | 4 | CHASE RANDAL D — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — GeoVax Labs, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — GeoVax Labs, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299807 (S-1) — latest: Initial registration (S-1), filed 2026-11-04
- SEC file 333-298989 (S-1) — latest: Initial registration (S-1), filed 2026-09-17
GET https://api.filingpulse.io/v1/insider-trades?ticker=GOVX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs